Comparative Pharmacology
Head-to-head clinical analysis: AFEDITAB CR versus CARDENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFEDITAB CR versus CARDENE.
AFEDITAB CR vs CARDENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
20-40 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker